---
document_datetime: 2025-04-16 14:51:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_en.pdf
document_name: translarna-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9481603
conversion_datetime: 2025-12-17 22:40:10.470153
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| EU Number       | (Invented) name   | Strength   | Pharmaceutical Form          | Route of Administration   | Immediate Packaging   | Pack size   |
|-----------------|-------------------|------------|------------------------------|---------------------------|-----------------------|-------------|
| EU/1/13/902/001 | Translarna        | 125 mg     | Granules for oral suspension | Oral use                  | sachet (alu)          | 30 sachets  |
| EU/1/13/902/002 | Translarna        | 250 mg     | Granules for oral suspension | Oral use                  | sachet (alu)          | 30 sachets  |
| EU/1/13/902/003 | Translarna        | 1000 mg    | Granules for oral suspension | Oral use                  | sachet (alu)          | 30 sachets  |

<!-- image -->